NEW YORK--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) will release its first quarter financial results before the market opens on May 8, 2007. Antigenics executives will host a conference call at 11:00 a.m. ET that same day. Andrew T. Parsa, MD, PhD, assistant professor in the department of neurological surgery at the University of California, San Francisco, and lead investigator for the Phase 1/2 study of Oncophage® (vitespen) in recurrent glioma, will participate on the call to provide investors with an update on the trial that was recently presented at a scientific conference.
